Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Arizona

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Targeted Legal Advocacy

For decades, general health and science communication has served as the foundation for public understanding of medical risks and treatment options. This legacy context emphasized broad awareness of pharmaceutical benefits and side effects, often framed within population-level guidelines and preventive care. As scientific literacy expanded, so did the recognition that certain medications carry rare but serious adverse outcomes, prompting more focused scrutiny on individual patient experiences and legal accountability. Within this evolving landscape, the transition from general health information to specific occupational and pharmaceutical exposure concerns becomes necessary. One notable example involves bisphosphonate drugs like Fosamax, widely prescribed for bone density maintenance, yet later associated with osteonecrosis of the jaw—a condition where jawbone tissue fails to heal after minor trauma. While the initial health discourse centered on efficacy and routine monitoring, subsequent attention shifted to the implications of prolonged exposure, particularly among patients undergoing dental procedures or those with pre-existing oral health vulnerabilities. This pivot underscores a broader movement from passive health awareness to active risk management, where understanding the statute of limitations for legal recourse in jurisdictions such as Arizona becomes critical.

Medical Evidence: Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate use, including Fosamax. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is rare, as indicated by research showing that atypical femoral fracture or osteonecrosis of the jaw is uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The safety profile of Fosamax 70 mg once weekly was assessed in a one-year study comparing it to Fosamax 10 mg daily, and the overall safety and tolerability profiles were similar (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Statute of Limitations for Fosamax Claims in Arizona

From a medical risk perspective, patients who have taken Fosamax and developed ONJ should be aware of the potential link between the drug and this condition. The adequacy of warnings regarding Fosamax and ONJ is a key consideration. The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the time to onset of symptoms can vary, and some patients may not immediately associate their dental issues with the medication. For affected patients in Arizona, attorney-related considerations involve the statute of limitations for filing a claim. The statute of limitations is a legal time limit within which a lawsuit must be filed. In Arizona, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. This means that patients who have developed ONJ after taking Fosamax must be aware of this timeline to preserve their legal rights. The timeline between exposure to Fosamax and documented harm is critical, as ONJ can develop months or even years after starting the medication. Patients should consult with a qualified attorney to understand how the statute of limitations applies to their specific case, especially given that the onset of symptoms can be delayed. In summary, Fosamax is associated with a rare but serious risk of ONJ, particularly in patients with additional risk factors such as invasive dental procedures or poor oral hygiene. The prescribing information includes warnings about this risk, but patients should be vigilant for symptoms such as jaw pain, swelling, or delayed healing after dental procedures. For those considering legal action in Arizona, the statute of limitations is a crucial factor, and prompt consultation with an attorney is advisable to ensure timely filing of any claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Arizona?

In Arizona, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Fosamax, is generally two years from the date the injury was discovered or should have been discovered. This means that patients who developed osteonecrosis of the jaw after taking Fosamax must file a lawsuit within two years of discovering the link between their injury and the medication. Because ONJ symptoms can appear months or years after starting Fosamax, it is crucial to consult an attorney promptly to ensure the claim is filed within the legal deadline.

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors for osteonecrosis of the jaw (ONJ) in patients taking bisphosphonates like Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.